Black Diamond director granted 40,000 stock options

Black Diamond Therapeutics director Samarth Kulkarni received a grant of stock options covering 40,000 shares of common stock.

Rhea-AI Filing Summary

Black Diamond Therapeutics director Samarth Kulkarni received a grant of stock options covering 40,000 shares of common stock. These options have an exercise price of $1.71 per share and are held directly in his name.

The options vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, as long as he continues to serve through that vesting date. After this grant, he holds options to acquire 40,000 shares, and there are no open-market purchases or sales reported in this filing.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Kulkarni Samarth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options granted: 40,000 shares Exercise price: $1.71 per share Expiration date: June 25, 2036 +2 more

5 metrics

Options granted 40,000 shares Stock Option (Right to Buy) grant to director

Exercise price $1.71 per share Exercise price of granted stock options

Expiration date June 25, 2036 Option term end date

Vesting date trigger June 26, 2027 Earlier of this date or next annual meeting

Options after transaction 40,000 shares Total options held following this grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.7100" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders"

expiration date financial

"expiration_date: "2036-06-25T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Black Diamond Therapeutics (BDTX) director Samarth Kulkarni report on this Form 4?

Director Samarth Kulkarni reported receiving a grant of stock options for 40,000 shares of Black Diamond Therapeutics common stock at an exercise price of $1.71 per share, vesting based on future service and corporate meeting timing.

How many Black Diamond Therapeutics (BDTX) options did Samarth Kulkarni receive and at what price?

Samarth Kulkarni received stock options covering 40,000 shares of Black Diamond Therapeutics common stock with an exercise price of $1.71 per share. These options give him the right, but not the obligation, to buy shares at that price once vested.

When do Samarth Kulkarni’s new BDTX stock options vest?

Kulkarni’s options vest and become exercisable in full on the earlier of June 26, 2027 or Black Diamond Therapeutics’ next annual meeting of stockholders, provided he continues to serve the company through the applicable vesting date.

Does this Black Diamond Therapeutics Form 4 show any open-market buying or selling by Samarth Kulkarni?

The Form 4 does not show any open-market purchases or sales. It reports only a grant of stock options as compensation, meaning no shares were bought or sold in the market as part of this specific filing.

How many BDTX option shares does Samarth Kulkarni hold after this transaction?

After the reported grant, Kulkarni holds stock options covering 40,000 shares of Black Diamond Therapeutics common stock. This figure reflects the derivative position from this award; other share holdings, if any, are not detailed here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:37 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

ONE MAIN STREET, 14TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.71	06/26/2026		A		40,000		(1)	06/25/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)